AAM Statement on Signing USMCA into Law | Association for Accessible Medicines
On the Blog - Jonathan Kimball gives more detail re: AAM's blueprint & proposed policy framework

AAM Statement on Signing USMCA into Law

WASHINGTON DC (January 29, 2020) – “The Association for Accessible Medicines applauds President Trump’s signing of the U.S.-Mexico-Canada Agreement, the new gold standard for free trade agreements. Not only will patients have greater access to affordable medicines as a result of the USMCA, but America’s patients can be assured that this agreement promotes competition, access and innovation, the three building blocks of America’s globally leading pharmaceutical industry. As the Trump administration continues to pursue trade negotiations with the UK, Japan, the EU and others, the USMCA will serve as the template for ensuring open competition that benefits the U.S. economy and America’s patients.”

ATTRIBUTE TO: Chip Davis, President and CEO

 

MEDIA CONTACT:
Rachel Schwartz
202.249.7147 

 

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending. 

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.

 

Issues

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.